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The Wilson protein (ATP7B) is a copper-transporting CPx-type
ATPase defective in the copper toxicity disorder Wilson disease.
In hepatocytes, ATP7B delivers copper to apo-ceruloplasmin and
mediates the excretion of excess copper into bile. These distinct
functions require the protein to localize at two different sub-
cellular compartments. At the trans-Golgi network, ATP7B tran-
sports copper for incorporation into apo-ceruloplasmin. When
intracellular copper levels are increased, ATP7B traffics to post-
Golgi vesicles in close proximity to the canalicular membrane
to facilitate biliary copper excretion. In the present study, we
investigated the role of the six N-terminal MBSs (metal-binding
sites) in the trafficking process. Using site-directed mutagenesis,
we mutated or deleted various combinations of the MBSs and
assessed the effect of these changes on the localization and traf-
ficking of ATP7B. Results show that the MBSs required for
trafficking are the same as those previously found essential for the
copper transport function. Either MBS 5 or MBS 6 alone was
sufficient to support the redistribution of ATP7B to vesicular com-
partments. The first three N-terminal motifs were not required
for copper-dependent intracellular trafficking and could not func-
tionally replace sites 4–6 when placed in the same sequence pos-
ition. Furthermore, the N-terminal region encompassing MBSs
1–5 (amino acids 64–540) was not essential for trafficking, with
only one MBS close to the membrane channel, necessary and suf-
ficient to support trafficking. Our findings were similar to those
obtained for the closely related ATP7A protein, suggesting similar
mechanisms for trafficking between copper-transporting CPx-
type ATPases.
Key words: ATP7B, copper, P-type ATPase, trafficking, Wilson
disease, WND.
INTRODUCTION
CPx-type ATPases are transmembrane proteins that carry out
ATP-driven translocation of metal cations across cellular mem-
branes. Members of this family have been identified in bacteria,
yeast, nematodes, mammals and plants, and translocate a variety
of metals including copper, silver, zinc, lead and cadmium [1].
Two homologous human proteins, ATP7A (Menkes protein)
and ATP7B (Wilson protein), are copper-transporting CPx-type
ATPases that have eight predicted transmembrane domains and six
N-terminal MBSs (metal-binding sites) [2–6]. Each binding motif
contains the signature sequence of heavy metal-binding proteins,
GMXCXXC. The N-termini of both ATP7A and ATP7B have
been shown to bind copper preferentially (relative to cadmium,
cobalt or zinc) with a stoichiometry of one copper atom per bind-
ing repeat [7]. Copper binds in its reduced state Cu+ to the GMX-
CXXC motif via the cysteine residues [7,8]. ATP7A and ATP7B
share 59% amino acid sequence identity and differ in their tissue
expression patterns. ATP7B is predominantly expressed in the
liver [9], whereas ATP7A is expressed in most non-hepatic tissues
[10]. The essential role of both CPx-type ATPases in maintaining
copper homoeostasis is illustrated by the severe nature of the
genetic copper disorders Menkes and Wilson diseases [11].
Immunocytochemical analysis of mammalian cell lines expres-
sing either ATP7A or ATP7B has revealed that both proteins re-
side at the TGN (trans-Golgi network) [12–14]. At this location,
both proteins translocate copper into the TGN lumen for in-
corporation into copper-dependent apo-enzymes as they migrate
Abbreviations used: BME, Eagles basal medium; CHO, Chinese-hamster ovary; ER, endoplasmic reticulum; FCS, foetal calf serum; MBS, metal-binding
site; TGN, trans-Golgi network; wt, wild-type.
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through the secretory pathway [15,16]. In hepatocytes, an in-
crease in copper levels results in trafficking of ATP7B from the
TGN to pericanalicular vesicles and then ATP7B recycles back to
the TGN when copper levels are restored [14]. The trafficking
of ATP7B represents a transition in function, from a role in bio-
synthesis of holo-ceruloplasmin at the TGN [15] to copper export/
homoeostasis, involving post-Golgi vesicular compartments and
excretion into bile [14,17]. The steady-state localization of ATP7B
depends on copper levels, although, recycling is probably con-
stitutive in the presence of either high or low copper levels (S. La
Fontaine and J. F. B. Mercer, unpublished work). In non-hepatic
cells, ATP7B traffics to a dispersed population of cytoplasmic
vesicles, possibly involved in sequestering excess copper as a
means of detoxification [18,19]. Studies on the subcellular local-
ization of ATP7A have shown a similar trafficking behaviour with
copper-induced redistribution from the TGN to cytosolic vesicular
compartments and the plasma membrane [12,13].
One proposed role for the N-terminal copper-binding sites of
ATP7A and ATP7B is that they individually or co-operatively
act as a copper sensor, regulating the subcellular localization of
the ATPase depending on the copper status of the cell. Several
recent findings on ATP7B have supported this proposal [20,21].
Structural analysis of the N-terminus has revealed that both secon-
dary and tertiary structural changes take place after the binding
of copper [20]. Furthermore, it was demonstrated that copper co-
ordination induces the phosphorylation of ATP7B, which coin-
cides with the trafficking of the protein to vesicular compartments
[21].
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The role of the N-terminal domain in the copper transport
activity of ATP7B has been investigated using a yeast comple-
mentation assay [22]. In Saccharomyces cerevisiae, the ATP7B
orthologue Ccc2p transports copper to the ferroxidase Fet3p [23],
which is analogous to ATP7B-mediated transport of copper to
apo-ceruloplasmin in mammalian hepatocytes [15]. ATP7B can
complement a yeast strain that lacks ccc2 expression (ccc2)
indicating that ATP7B can transport copper to Fet3p [9]. In
addition, complementation of the ccc2 mutant with ATP7B N-
terminal variants showed that the copper-binding sites closest to
transmembrane domain 1 were more important for the copper-
transporting activity than the sites closer to the N-terminus [22].
Therefore it was postulated that copper co-ordination by MBSs
closest to the N-terminus may be involved in initiating copper-
dependent trafficking of ATP7B to vesicular compartments [22].
The objective of the present study was to test this hypothesis and
to clarify the role of the N-terminal MBSs in ATP7B trafficking.
We report that there is no difference in the MBS requirement for
the copper transport and the copper-induced trafficking activity
of ATP7B. Furthermore, trafficking of ATP7B does not depend
on co-operative copper binding to the N-terminal domain, with
only one MBS close to the channel, necessary and sufficient to
support trafficking. In addition, our results now enable a detailed
comparison of the role of the N-terminal MBSs between ATP7A
and ATP7B and suggests a functional conservation of the MBSs in
copper-induced trafficking and copper transport of these CPx-type
ATPases.
EXPERIMENTAL
Bacterial and yeast strains, cell culture and stable transfections
Escherichia coli DH5α [φ80clac ZM15, (lacZYA-argF)U169
recA endA1 hsdR17 (rK−, mK+) supE44 λ-thi-1 gyrA relA1],
used for the propagation of plasmids, was cultured in Luria–
Bertani medium (0.1% trypticase peptone, 0.1% NaCl and
0.05% yeast extract) containing 100 µg/ml ampicillin for plas-
mid selection. The S. cerevisiae mutant strain, ccc2∆ (MATα,
his3-200, trp-1-101, ura3-52, leu2, ade5, CCC2∆::LEU2) [24],
was cultured on YPD plates [2% (w/v) trypticase peptone/1%
(w/v) yeast extract/2% (w/v) glucose/2% (w/v) agar]. This strain
was transformed with plasmid DNA using a lithium acetate
method as described previously [25] and transformants were
selected on DOB-ura [0.66% yeast nitrogen base without amino
acids, 2% glucose and 0.08% CSM (complete supplement mix-
ture)-uracil]. CHO (Chinese-hamster ovary)-K1 cells for trans-
fection and immunofluorescence studies were cultured at 37 ◦C as
monolayers in BME (Eagles basal medium) (Trace BioSciences,
Nobel Park, Victoria, Australia), supplemented with 0.2 mM
proline, 10% (v/v) FCS (foetal calf serum), 2 mM L-glutamine,
1.2 mM NaHCO3 and 20 mM Hepes (Commonwealth Serum
Laboratories, Broadmeadows, Victoria, Australia). Transfection
of plasmid DNA into CHO-K1 cells was performed using
LIPOFECTAMINETM (Life Technologies, Mount Waverley,
Victoria, Australia) according to the manufacturer’s instructions.
Briefly, CHO-K1 cells were seeded in 25 cm2 flasks and allowed
to grow to 50% confluence. Approx. 10 µg of purified plasmid
DNA (5 µg linearized with BglII) was mixed with 20 µl of
LIPOFECTAMINETM (Life Technologies) and brought to 400 µl
with FCS-free BME. The DNA/LIPOFECTAMINETM mixture was
incubated at room temperature (20–25 ◦C) for 30 min, and then
made to a total volume of 1.5 ml with FCS-free BME. After 3 h of
incubation with the DNA/LIPOFECTAMINETM mixture, the cells
were allowed to recover overnight in BME containing 10% FCS
and the transfectants were selected using 500 µg/ml G418 (Life
Technologies) for 14 days. G418-resistant colonies were pooled
and analysed for ATP7B expression by immunofluorescence.
Generation of sheep polyclonal antibodies (NC36) against ATP7B
The amino acids 1–199 (N-terminal), 1309–1315 and 1376–1465
(C-terminal) of ATP7B were expressed as a 36-kDa fusion
protein with a His6 tag at the N-terminus of the protein. To
generate the expression construct, nt 1–597 and 4126–4395 of the
ATP7B cDNA were amplified through PCR. The oligonucleotides
5′-GGGCTCTAGAGGATCCATGCCTGAACAGGAGAGA-3′
(hWND#24) and 5′-GGGGCCTCGAGGCTAGCGTCCCTG-
AGGTCTTCGGGCTG-3′ (hWND#23), used to amplify the frag-
ment encoding the N-terminal amino acids, incorporated a BamHI
site directly upstream of the start codon and a NheI site at the
3′ end. The oligonucleotides 5′-GGGCTCTAGAGTGGTGGCT-
AGCATTCACCTTTCCAGGTATAAGAAGCCTGACCTGGA-
GAGGTATGAG-3′ (hWND#31) and 5′-GGGCTCTAGAGTCG-
ACTCATCAGATGTACTGCTCCTCATCCCT-3′ (hWND#30),
used to amplify the fragment encoding the C-terminal region,
introduced a SalI site directly downstream of the stop codon and
a native NheI site at the 5′ end. The two PCR products were
digested appropriately and ligated with BamHI–SalI-digested
pProEX HT-b vector (Gibco), generating the expression construct
pCMB430. The integrity of the construct was confirmed by
sequencing.
Expression was induced in E. coli DH5α cells grown to an A600
0.6 using 1 mM isopropyl β-D-thiogalactoside for 4 h at room
temperature. The recombinant protein was discovered to be ex-
tremely insoluble and was therefore purified by nickel-affinity
chromatography under denaturing conditions with a buffer con-
taining 8 M urea (100 mM NaH2PO4 · H2O, 10 mM Tris and 8 M
urea). The E. coli lysate was incubated with Ni2+-nitrilotriacetate–
agarose resin (1 ml resin/4 ml lysate) (Qiagen, Hilden, Germany)
for 1 h with constant agitation. The protein–resin mixture was
applied to a column and washed with 20 vol. of wash buffer
(100 mM NaH2PO4 · H2O/10 mM Tris/8 M urea, pH 6.5), before
the target protein was eluted with several fractions of elution buffer
(250 µM imidazole/100 mM NaH2PO4 · H2O/10 mM Tris/8 M
urea, pH 4.5). Purified protein was dialysed against several
changes of PBS and resuspended in PBS containing 1% SDS to
overcome problems with hydrophobicity. Protein concentration
was measured by the Bradford method (Pierce) and approx.
10 µg was subjected to fractionation by SDS/PAGE (12% gel).
Protein purity was ascertained by Coomassie staining [50% (v/v)
methanol, 10% (v/v) acetic acid and 0.1% (w/v) Coomassie
dye]. Five 400 µl aliquots, each containing 2.5 mg of dialysed
protein, were supplied to the IMVS (Institute of Medical and
Veterinary Sciences, University of Adelaide, SA, Australia) for
immunization of a sheep. The IgG fraction of the antiserum was
ammonium sulphate precipitated as described previously [26].
The antibody was designated NC36.
To determine if both the N- and C-terminal segments of the
fusion protein were immunogenic, each region was expressed and
purified separately and the ability of NC36 to detect both regions
was tested by Western-blot analysis (Figure 2B). To generate the
N-terminal (amino acids 1–199) expression construct, pCMB430
was digested with NheI–XbaI to drop out the region encoding
the C-terminus, and re-ligated to generate plasmid pCMB431.
To create the C-terminal expression construct, nt 3935–3945
and 4126–4395 of hATP7B were isolated from pCMB430 by
digestion with NheI–SalI and subcloned into the XbaI–XhoI sites
of pProEX HT-b to generate plasmid pCMB432. The N- and C-
terminal proteins, including the translated vector sequence, were
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Figure 1 Schematic representation of mutations and deletions introduced
into the N-terminus of ATP7B
(A) Shaded boxes denote MBS mutated from CXXC to SXXS, normal MBSs are indicated by
white boxes. (B) N-terminal deletions are represented by open rectangles with deleted amino
acids indicated. The vertical black bar represents the transmembrane domain 1. Diagrams are
orientated N- to C-termini (left to right) and are not to scale.
30 and 15 kDa respectively. Expression and purification of both
the proteins were performed as described above.
Wild-type (wt) and mutant ATP7B expression constructs
The ATP7B cDNA constructs (with the exception of MBS 1-4 +
6c/s) were generated previously [22]. Briefly, both cysteine re-
sidues within each of the metal-binding domains (GMXCXXC)
were mutated in separate plasmid constructs to serine. Using
native restriction sites, full-length constructs containing different
combinations of active and mutated MBSs were generated (Fig-
ure 1A). N-terminal domain deletion constructs were also created
by PCR (Figure 1B). The ATP7B cDNA constructs were originally
generated in the yeast expression vector pG3. Excision of the mu-
tated cDNAs was performed using BamHI and SalI, and the di-
gested fragments were cloned into the XhoI–SalI sites of the mam-
malian expression vector pCMB77 [13]. For several of the mutant
constructs, the excised fragments were also subcloned into the
BamHI–SalI sites of pWSK29 to enable more convenient gene-
ration of other constructs. Final plasmid constructs were desig-
nated as shown in Table 1. The ATP7B construct with MBSs
1-4 + 6 mutated (MBS 1-4 + 6c/s, Figure 1A) was created by
ligating a 2.6 kb NheI–EcoRI fragment (MBS 5 intact, 6 mutated)
isolated from pCMB417, with a 1.3 kb EcoRI–XbaI fragment
(MBS 1-4 mutated) from pCMB414 and NheI cut pCMB77 to
generate pCMB409. The correct orientation of the cDNA con-
struct was verified by restriction digestion profiles and the appro-
priate metal binding and ligation sites sequenced to confirm
integrity.
For expression in ccc2 yeast, wt ATP7B and mutated con-
structs were generated in the yeast expression vector pVT-103U
Table 1 Plasmids generated and used in the present study
Plasmid designation Characteristics Reference
pWSK29 Bacterial propagation vector [43]
pCMB77 Mammalian expression vector [13]
pVT-103U Yeast expression vector [27]
pProEX HT Bacterial expression vector Gibco
pCMB278 ATP7B-wt in pCMB77 This study
pCMB398 MBS 1-6c/s in pCMB77 This study
pCMB399 MBS 1-5c/s in pCMB77 This study
pCMB400 MBS 1-4c/s in pCMB77 This study
pCMB401 MBS 3-5c/s in pCMB77 This study
pCMB402 MBS 6c/s in pCMB77 This study
pCMB403 MBS 1-6del in pCMB77 This study
pCMB404 MBS 1-5del in pCMB77 This study
pCMB405 MBS 4-6del in pCMB77 This study
pCMB406 MBS 3-5del in pCMB77 This study
pCMB407 MBS 3-6del in pCMB77 This study
pCMB413 MBS 1-6c/s in pWSK29 This study
pCMB414 MBS 1-5c/s in pWSK29 This study
pCMB417 MBS 6c/s in pWSK29 This study
pCMB554 ATP7B-wt in pVT-103U This study
pCMB555 MBS 1-2c/s in pVT-103U This study
pCMB557 MBS 1-6c/s in pVT-103U This study
pCMB558 MBS 1-4 + 6c/s in pVT-103U This study
pCMB430 NC36 antigen in pProEX HT This study
pCMB431 N-terminus (N30) in pProEX HT This study
pCMB432 C-terminus (C15) in pProEX HT This study
[27]. Nucleotides 1–1937 of hATP7B were amplified through
PCR using the oligonucleotides 5′-CCCGATAGCGGATCCAT-
GCCTGAACAGGAGAGACAGATCACAGCC-3′ (hWND#34)
and 5′-CCATCTTGTGGTCCAAGAGATGAGC-3′ (hWND#7).
Two cDNA templates, pCMB413 and pCMB278, were used to
generate a PCR fragment with MBSs 1–2 mutated and the cor-
responding wt fragment respectively. Both PCR fragments were
digested with BamHI (introduced upstream ATG) and BseAI (na-
tive) to produce a 499 bp fragment, which was then ligated sepa-
rately with a BseAI–BamHI fragment isolated from pCMB277
into BamHI-digested pVT-103U (wt-ATP7B-pCMB554 and MBS
1-2 c/s-pCMB555). MBS 1-6c/s and MBS 1-4 + 6c/s in pVT-
103U were generated by isolating a BseAI–SalI fragment from
pCMB413 and pCMB409 respectively, which were used sepa-
rately to replace the corresponding region in pCMB555 (BseAI–
XhoI) (MBS 1-6c/s-pCMB557 and MBS 1-4 + 6c/s-pCMB558).
The integrity of the constructs was confirmed by sequencing.
Protein preparations and Western blotting
For the analysis of protein expressed in mammalian cells, cells
were harvested from confluent 75 cm2 flasks and centrifuged at
1000 g for 5 min. Cell pellets were washed once with PBS, re-
suspended in buffer (1% SDS/10 mM Tris/HCl) and sonicated
(Fisher Scientific Model 550 Sonic Dismembrator) using a micro-
tip probe, amplitude setting 3, 2 cycles of 30 s followed by 60 s
cooling on ice. Yeast protein extracts were prepared using the
trichloroacetic acid method as described in the Clontech’s Yeast
Protocols Handbook (PT3024-1). Whole-cell protein extract
(50 µg) was fractionated by SDS/PAGE (7.5% gel). After electro-
phoretic separation, proteins were transferred to nitrocellulose
(Amersham Biosciences) and immunoblot analysis was per-
formed using the Lumi-Light Chemiluminescence blotting kit
(Roche) according to the manufacturer’s instructions. ATP7B
was detected using the ammonium sulphate-precipitated NC36
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antibody (diluted 1/1000), followed by horseradish peroxidase-
conjugated donkey anti-sheep IgG (Chemicon, Boronia, Victoria,
Australia) (1/4000).
Immunofluorescence microscopy
Transfected cells were seeded on 13 mm glass coverslips and
cultured in BME containing 10% FCS. At 50–70% confluence,
the growth medium was replaced with either the basal medium
(0.5–1 µM Cu) or a medium supplemented with 200 µM CuCl2.
After 2 h of incubation, cells were fixed using 4% (w/v) para-
formaldehyde in PBS for 10 min, then permeabilized with 0.1%
(v/v) Triton X-100 in PBS for 10 min. Cells were blocked in
1% (w/v) BSA and 1% (w/v) gelatin in PBS at 4 ◦C overnight.
Coverslips were incubated with ammonium sulphate-precipitated
NC36, diluted 1/10000 in blocking solution for 1 h. After four
PBS washes (15 min each), coverslips were incubated with the
secondary antibody, donkey anti-sheep IgG Alexa 488 (1/4000)
(Chemicon) and again washed with PBS as above. Coverslips
were mounted on glass slides using 2.6% (w/v) 1,4-diazadi-
cyclo[2.2.2]octane (Sigma) in 90% (v/v) glycerol. Immuno-
labelled cells were analysed using a ×60-oil objective with an
Olympus PROVIS AX70 microscope.
Yeast complementation assay
Complementation of ccc2∆ yeast using the constructs MBS1-
6c/s, MBS1-4 + 6c/s and wt-ATP7B (Table 1) was performed by
a method adapted from previously described procedures [9,28].
Briefly, 10 ml of DOB-ura was inoculated (in duplicate) with the
appropriate yeast strain and grown at 30 ◦C overnight. Cells were
pelleted by centrifugation (10 min, 3500 g), washed twice with
ice-cold double distilled H2O, then resuspended in iron-limited
DOB-ura (50 mM Mes/250 µM ferrozine in DOB-ura) and again
allowed to grow overnight. Cells were pelleted and washed as
before and resuspended in fresh iron-limited media (50 ml) to a
cell density of A600 0.01. Growth rates of the yeast strains were
analysed spectroscopically and measurements (A600) were taken
at times 0, 10–24 (2 h intervals) and 36 h. The linear exponential
growth phase between 12 and 20 h from duplicate experiments
(averaged) was used to determine the growth rate, which was the
gradient of the trend line. The copper transport activity of MBS1-
4 + 6c/s was also assessed by growth on iron-limited plates as
described previously [28].
RESULTS
Generation of ATP7B constructs and anti-ATP7B antibody (NC36)
The role of the N-terminal MBSs of ATP7B in intracellular traf-
ficking was investigated using site-directed and deletion muta-
genesis. Constructs encoding ATP7B with different combinations
of wt (CXXC) and mutated (SXXS) MBSs (Figure 1A), or har-
bouring N-terminal deletions (Figure 1B), were expressed in
CHO-K1 cells. To enable detection of the expressed proteins, a
polyclonal antibody (NC36) was raised in sheep against a 36 kDa
fusion protein comprising amino acids 1–199 (N-terminus),
1309–1315 and 1376–1465 (C-terminus) of ATP7B (as described
in the Experimental section). The specificity of the antibody was
tested by Western-blot analysis (Figure 2A). The antibody spe-
cifically detected a single 165 kDa protein in lysates from HepG2
and PMC-42 cell lines (Figure 2A), which have been previously
shown to express ATP7B [14]. No protein was detected in lysate
from CHO-K1 cells (Figure 2A), nor in HepG2 or PMC-42 cell
lines when immunoblots were incubated with preimmune serum
Figure 2 Characterization of anti-ATP7B antibody (NC36) by Western-blot
analysis
(A) Total protein (50 µg) from the cell types indicated was separated by SDS/PAGE (7.5 % gel)
and transferred on to a nitrocellulose membrane. Protein was immunolabelled with ammonium
sulphate-precipitated NC36 (diluted 1/1000), followed by horseradish peroxidase-conjugated
donkey anti-sheep IgG (diluted 1/4000) and analysed by chemiluminescence. HepG2, human
hepatoma cell line; PMC-42, human breast carcinoma cell line. (B) The N- (N30) and C-terminal
(C15) segments of the ATP7B antigen (NC36) used to generate the antibody were expressed and
purified separately to test immunogenicity. Each lane contained approx. 1 µg of purified protein
and was detected using the above conditions. The position of the molecular-mass standards
(Bio-Rad) are indicated on the left in kDa.
or secondary antibody alone (results not shown). To demonstrate
that antibodies were raised against both the N- and C-terminal
segments of the ATP7B fusion protein, each region was expressed
and purified separately and detected by Western-blot analysis
(Figure 2B).
Expression of wt, mutated and truncated ATP7B proteins
in CHO-K1 cells
Immunofluorescence microscopy was performed on CHO-K1
cells stably expressing wt and mutated forms of ATP7B. Ini-
tially, several of the constructs were transiently transfected into
CHO-K1 cells; however, the results were difficult to interpret
because expression levels were extremely variable, ranging from
barely detectable to overexpression causing mislocalization (re-
sults not shown). Therefore stable cell lines were generated for
all constructs, allowing trafficking to be assessed in cells expres-
sing consistent levels of the target protein. In all cell lines gene-
rated, except as indicated below, a single protein band of the
expected mass was detected by the NC36 antibody (Figure 3A).
Under basal copper conditions (0.5–1 µM Cu), cells expressing
wt ATP7B displayed fluorescent staining within the perinuclear
region (Figure 4C), which is consistent with previously described
TGN localization of ATP7B [14,29–31]. Intracellular trafficking
of ATP7B was induced by incubating the cells for 2 h in media
supplemented with 200 µM CuCl2 (Figure 4D). As a result of
copper treatment, the intensity of the perinuclear staining de-
creased, with a predominant vesicular-like staining throughout
the cytoplasm (Figure 4D). NC36 antibody used on CHO-K1
cells transfected with the mammalian expression vector alone
(pCMB77) showed minimal cross-reactivity with endogenous
proteins (Figures 4A, 4B and 5A, 5B).
Effect of N-terminal MBS mutations (CXXC-SXXS)
on the trafficking of ATP7B
Mutation of the cysteines in all six MBSs to serines (MBS
1-6c/s) abrogated the copper-induced redistribution of ATP7B,
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Figure 3 Western-blot analysis of CHO-K1 cells and ccc2 yeast
expressing ATP7B variants
(A,B) Total cellular protein (50 µg) was separated by SDS/PAGE (7.5 % gel) and transferred on to
a nitrocellulose membrane. Protein was immunolabelled with ammonium sulphate-precipitated
NC36 (diluted 1/1000), followed by horseradish peroxidase-conjugated donkey anti-sheep IgG
(diluted 1/4000) and analysed by chemiluminescence. Western blots comparing the expression
levels of the indicated ATP7B constructs stably expressed in CHO-K1 cells (A) and expressed
in ccc2 yeast (B).
with perinuclear staining observed in the presence of both basal
and increased levels of copper (Figures 4E and 4F). Constructs
encoding ATP7B with different combinations of wt (CXXC)
and mutated (SXXS) MBSs were used to establish the MBSs
required for copper-induced trafficking. All of the mutated
proteins localized to the TGN in cells were cultured in basal media
(Figure 4, basal). When cells were incubated in 200 µM CuCl2 for
2 h, redistribution of ATP7B occurred in lines expressing MBS
1-5c/s, MBS 3-5c/s and MBS 6c/s, with a cytosolic vesicular
pattern indistinguishable from that of wt ATP7B (Figures 4H,
4L and 4N). In contrast, cells expressing MBS 4-6c/s maintained
the perinuclear staining in increased levels of copper (Figure 4J),
indicating that MBSs 1-3 were not sufficient for relocalization
of ATP7B. These results suggested that some or all three metal-
binding motifs closest to transmembrane domain 1 (MBS 4-6)
are required to support the trafficking activity. MBS 6 alone was
able to support the relocalization of ATP7B (MBS 1-5c/s) (Figure
4H), but since ATP7B with MBS 6 mutated (MBS 6c/s) was
still capable of trafficking (Figure 4N), this indicated that MBS 6
was not essential. To determine if MBS 5 alone could also support
copper-induced trafficking, the construct MBS 1-4 + 6c/s (5 alone
intact) was generated (Figure 1A). MBS 1-4 + 6c/s had a TGN
localization in cells cultured in basal media (Figure 4O) and a
cytosolic vesicular localization indistinguishable from that of wt
ATP7B in media supplemented with 200 µM CuCl2 (Figure 4P).
The redistribution of MBS 1-4 + 6c/s illustrated that the presence
of MBS 5 alone is sufficient to allow the trafficking of ATP7B.
Effect of N-terminal deletions on the trafficking of ATP7B
To establish if the amino acids surrounding the MBSs (GMX-
CXXC) are also required for copper-induced redistribution, the
trafficking ability of ATP7B constructs with large N-terminal
deletions (Figure 1B) was assessed. In CHO-K1 cells, several
of the truncated proteins exhibited an alternative subcellular
localization in comparison with wt ATP7B. Deletion of MBSs
Figure 4 Immunofluorescence microscopy of CHO-K1 cells expressing
ATP7B wt and N-terminal MBS mutants
CHO-K1 cells transfected with the indicated construct were cultured in basal media (0.5–
1 µM Cu) or in media supplemented with 200 µM CuCl2. Immunofluorescence detection was
performed by incubation with ammonium sulphate-precipitated NC36 (diluted 1/10 000) and
donkey anti-sheep IgG Alexa 488 (diluted 1/4000).
1-6 (MBS 1-6del), 3-5 (MBS 3-5del) and 3-6 (MBS 3-6del) re-
sulted in proteins that were distributed in a reticulated pattern
throughout the cytoplasm (Figures 5C, 5D and 5I–5L). This
phenotype was observed in all of the transfected cells irrespective
of expression level and the addition of 200 µM CuCl2 to the
growth media had no effect on the localization. The truncated
ATP7B in cells expressing MBS 3-5del and MBS 3-6del could
not be detected by Western blot and only marginal amounts of
intact protein were detected in cells expressing MBS 1-6del (Fig-
ure 3A). This result was consistent with a decrease in the number
of cells expressing these mutant proteins and with the decrease
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Figure 5 Immunofluorescence microscopy of CHO-K1 cells expressing
ATP7B N-terminal deletion mutants
CHO-K1 cells transfected with the indicated construct were cultured in basal media (0.5–1 µM
Cu) or media supplemented with 200 µM CuCl2. Immunofluorescence detection was performed
by incubation with ammonium sulphate-precipitated NC36 (diluted 1/10 000) and donkey anti-
sheep IgG Alexa 488 (diluted 1/4000).
in immunofluorescence labelling of cells that did express these
mutant proteins. These results suggested that the truncated pro-
teins MBS 1-6del, MBS 3-5del and MBS 3-6del are unstable
and localized to the ER (endoplasmic reticulum), typical of other
misfolded ATP7B variants [18,29]. MBS 1-6del co-localized with
the ER protein, protein disulphide isomerase (results not shown).
Two deletion mutants (MBS 1-5del and MBS 4-6del) did pre-
serve a perinuclear distribution indistinguishable from the local-
ization of wt ATP7B under basal copper conditions (Figures 5E
and 5G). When copper levels were increased, however, only MBS
1-5del redistributed to post-Golgi vesicular compartments (Fig-
ure 5F), indicating that the amino acids surrounding MBS 6 were
sufficient for trafficking activity. The inability of MBS 4-6del to
undergo copper-induced trafficking, demonstrated that the first
three MBSs are not equivalent to and cannot replace sites 4–6,
even when placed in the same sequence position.
MBS 5 alone supports copper transport
Forbes et al. [22] established that MBS 6 alone is sufficient
for ATP7B to transport copper to Fet3p in ccc2 yeast. In the
Table 2 Comparison of the transport and trafficking ability of ATP7B N-
terminal variants
The ability of ATP7B N-terminal mutants to transport copper was assessed through ccc2
complementation. The growth rate of selected yeast strains was quantified and is shown as
the percentage of growth rate compared with wt-ATP7B. The linear exponential growth phase
between 12 and 20 h from duplicate experiments was used to determine the growth rate, which
was the gradient of the trend line. The localization of the same mutant proteins in CHO-K1 cells
exposed to both basal (0.5–1 µM) and increased levels (200 µM) of copper is shown. Nd, not
determined.
Localization in
Transport activity CHO-K1 cells*
Yeast strain/construct Plate growth assay† Growth rate (%) Basal + Cu
pVT-103U Inactive 2.9 +− 2.23* Nd Nd
Wt-ATP7B Active 100 +− 0.000* TGN Vesicles
MBS 1-6c/s Inactive 3.3 +− 0.92* TGN TGN
MBS 1-5c/s Active 101.5 +− 0.046† TGN Vesicles
MBS 4-6c/s Inactive Nd TGN TGN
MBS 3-5c/s Active Nd TGN Vesicles
MBS 6c/s Active Nd TGN Vesicles
MBS 1-4 + 6c/s Active* 72.5 +− 0.49* TGN Vesicles
MBS 1-6del Inactive Nd Diffuse Diffuse
MBS 1-5del Active 95 +− 0.037† TGN Vesicles
MBS 4-6del Inactive Nd TGN TGN
MBS 3-5del Inactive Nd Diffuse Diffuse
MBS 3-6del Inactive Nd Diffuse Diffuse
* This study.
† Results from Forbes et al. [22].
present study, we demonstrated that MBS 5 or MBS 6 alone can
support trafficking of ATP7B and postulated that this is also the
case for copper transport. To test this hypothesis, the ATP7B
construct with MBS 5 intact and all others mutated (MBS 1-
4 + 6c/s) was expressed in ccc2 yeast and evaluated for its
copper transport ability by assessing the growth of the transformed
yeast on solid iron-limited media and by measuring the growth rate
of the same transformant in iron-limited liquid media (Table 2).
Mutant (ccc2) yeast carrying the empty expression vector (pVT-
103U) or expressing MBS 1-6c/s were unable to grow in the
iron-limited media, consistent with previous results [22]. Yeast
strain viability was confirmed on iron-sufficient culture plates
(results not shown). Wt-ATP7B supported copper delivery to
Fet3p, allowing ccc2 yeast to grow on iron-depleted media.
MBS 1-4 + 6c/s could also complement ccc2 yeast; however,
the growth rate was slightly lower in comparison with wt-ATP7B
(approx. 72.5%), suggesting that the copper transport ability
of this molecule was somewhat reduced. Western-blot analysis
(Figure 3B) showed that the reduced growth rate of MBS 1-
4 + 6c/s was not due to a decreased protein level, with MBS
1-4 + 6c/s showing greater amounts of protein when compared
with the wt-ATP7B.
DISCUSSION
In cells exposed to increased levels of copper, ATP7B rapidly
shifts its steady-state localization from the TGN to cytoplasmic
vesicles and recycles back to the TGN when basal copper levels
are restored [19,30,32]. The ability of ATP7B to respond to
changes in cellular copper concentration has been proposed
to involve the six MBSs in the N-terminal region [7,22]. In this
report, we investigated the trafficking ability of ATP7B variants
containing different combinations of active (CXXC) and mutated
(SXXS) MBSs (Figure 4) or bearing N-terminal truncations
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(Figure 5). Mutation of the cysteine residues in all six MBSs
(GMXCXXC) to serine residues (GMXSXXS) completely abro-
gated ATP7B redistribution (Figures 4E and 4F), demonstrating
the necessity of copper binding to the N-terminal domain for regu-
lating the trafficking process. MBSs closest to the transduction
channel were more important for copper-induced trafficking than
the more N-terminal motifs. Metal binding sites 5 or 6 alone were
sufficient for the redistribution of ATP7B in increased levels of
copper (Figures 4G, 4H, 4O and 4P), whereas the first three MBSs
could not support the copper-mediated response (Figures 4I and
4J). Taken together, these results demonstrate that the trafficking
of ATP7B is not dependent on the presence of multiple MBSs
or co-operative binding of copper to the N-terminal domain and
suggests a functional difference between the first three MBSs
and those closer to the transduction channel.
A series of N-terminal deletion constructs were analysed for
trafficking activity to investigate whether amino acids other than
the cysteine residues in the MBSs (Figure 5) are essential. Several
of the truncated proteins (MBS 1-6del, MBS 3-5del and MBS
3-6del) when expressed in CHO-K1 cells displayed a cytosolic
reticulated pattern (Figures 5C, 5D and 5I–5L) and had little
(MBS 1-6del) or no (MBS 3-5del and MBS 3-6del) intact protein
when evaluated by Western-blot analysis (Figure 3). We suggest
that the mislocalization of these mutants when expressed in CHO-
K1 cells was due to folding irregularities, whereas the inability
to detect MBS 3-5del and MBS 3-6del by Western blot was due to
low transfection rates coupled with the probable rapid degradation
of the expressed misfolding proteins. When these same constructs
were previously transformed in yeast however [22], they were
expressed to a level similar to that of wt ATP7B. This discrepancy
may be explained, in part, by previously published observations
that ATP7B variants that misfold and localize to the ER in CHO-
K1 cells, are often stable when expressed in yeast [18]. In addition,
the stable CHO-K1 cell lines expressing these constructs had
lower transfection rates when compared with all other cell lines,
limiting the amount of these mutant proteins.
Nevertheless, two truncated proteins MBS 1-5del (Figures 5E
and 5F) and MBS 4-6del (Figures 5G and 5H) did provide con-
siderable insight into the N-terminal regions required for traf-
ficking. MBS 1-5del exhibited trafficking behaviour indistin-
guishable from that of wt ATP7B, indicating that the deleted
region (amino acids 64–540) did not contain any sequence essen-
tial for retention at the TGN or targeting to post-Golgi vesicular
compartments. This result also confirmed that only one MBS
close to the transmembrane channel is required for trafficking of
ATP7B. The inability of MBS 4-6del to undergo copper-mediated
trafficking illustrates that the first three MBSs are not functionally
equivalent to and cannot replace sites 4–6 when situated in the
same sequence position. This result is particularly important since
it further suggests that the sequence, or part thereof, surrounding
MBS 6 is specifically required for trafficking and cannot be
replaced by the other metal-binding domains. Recently, we have
shown that a putative targeting motif exists in the region of MBS 6,
which directs ATP7B to a vesicular compartment [33]. We further
suggest that this motif while important in targeting ATP7B to
vesicles may also be involved in initiating the trafficking process
itself, since its deletion perturbs the whole process.
Previously, Forbes et al. [22] have used functional comple-
mentation of S. cerevisiae ccc2 to determine the role of the
N-terminal metal-binding domain in ATP7B-mediated copper
transport to Fet3p. The ATP7B constructs analysed in this study
have all been tested for their ability to transport copper to Fet3p
and thereby correct the high-affinity iron uptake deficiency of
the ccc2 strain (Table 2). These results suggest that MBS 6
alone is capable of supporting normal copper transport ability of
ATP7B. The deletion of amino acids 63–540 (MBS 1-5del) did
not significantly impede the ability of ATP7B to complement the
ccc2 strain, indicating that most of the N-terminal domain is not
essential for copper transport. When MBS 5 alone is left intact
(MBS 1-4 + 6c/s), the growth rate is reduced to approx. 72%
when compared with that of ccc2 expressing wt-ATP7B. This
result is consistent with the recent results published by Huster and
Lutsenko [34], which showed that the catalytic phosphorylation
of ATP7B is decreased to 70% of the normal level when MBS
6 is mutated. Therefore it appears that although both MBSs 5
and 6 are capable of supporting copper transport, MBS 6 has a
more critical role, which possibly relates to its proximity to the
transduction channel.
Table 2 summarizes the trafficking behaviour of ATP7B N-
terminal mutants and relates this to their copper transport ability.
The trafficking behaviour of the various mutants corresponded to
their ability to transport copper. It is clear, as we have observed
with ATP7A [33], that ATP7B variants that are defective in copper
transport also cannot traffic. This observation is consistent with
our recent results, which demonstrated that the acyl-phosphate
intermediate of ATP7A is the form of the molecule that undergoes
trafficking [35]. Mutations that prevent the formation of the
acyl-phosphate intermediate inhibit movement from the TGN,
whereas mutation of the phosphatase domain traps the protein in
the acyl-phosphate form, which results in a constitutive plasma
membrane location for ATP7A and vesicular location for ATP7B
[35]. Therefore any mutation that prevents catalytic activation
(formation of the acyl-phosphate) will also prevent copper-
induced trafficking. This explains why the toxic milk mouse muta-
tion (M1356V) [31], the brindled mouse mutation (A799L800)
[36] and a missense mutation (A1362V) that causes mild Menkes
disease [37] result in proteins that are located in the TGN and
unable to traffic. Presumably, a specific conformation associated
with this acyl-phosphate intermediate is required for trafficking
[35], possibly by exposing an exocytic signal or occluding a
TGN retention sequence (not mutually exclusive). The shift in the
steady-state localization from the TGN can be explained by an
increase in the number of molecules that are catalytically activated
(acyl-phosphorylated) and proceed through the reaction cycle.
The Menkes protein (ATP7A or MNK) is highly similar to
ATP7B with respect to amino acid sequence, structure and cell
biology. Analogous to ATP7B, most of the N-terminus of ATP7A
(amino acids 8–485) is not required for either copper transport
[33], or trafficking [38], with MBS 5 or MBS 6 sufficient for
both processes. Thus, for both human CPx-type ATPases, the
same MBSs are important for their copper transport and copper-
induced trafficking activities. The role of the first four MBSs in
both ATP7A and ATP7B is not clear, although it has been postu-
lated that multiple metal-binding repeats may increase the efficacy
of cytoplasmic copper scavenging or copper delivery to the trans-
duction channel [38]. Conceivably, the first four MBSs when
bound to copper may also prolong the acyl-phosphorylated state
of the ATPase, increasing the likelihood for redistribution in the
face of increased intracellular copper levels.
The requirement for the copper-chaperone Atox1 in the traf-
ficking of ATP7A and in the control of intracellular copper levels
has been established [39], and by inference the chaperone may
also have a critical role in ATP7B trafficking. Earlier studies have
demonstrated a copper-dependent interaction between Atox1 and
both ATP7A and ATP7B N-terminal domains [40]. For ATP7B, it
has been demonstrated that the transfer of copper from Cu-Atox1
to ATP7B stimulates catalytic phosphorylation, but that copper
binding to all MBSs is not necessary to support the catalytic
activity of ATP7B [41,42], consistent with the results presented
in the present study.
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This study forms a part of a series of investigations, aimed at
elucidating the role of the six N-terminal MBSs in the copper
transport and copper-induced trafficking function of the human
CPx-type ATPases (ATP7A and ATP7B). From the results pre-
sented in this and other recent studies, a picture of the molecular
components and interactions necessary for the maintenance of
intracellular copper levels emerges, whereby cellular copper is
bound by Atox1, delivered and transferred to the MBSs of ATP7A
or ATP7B; conformational changes in the ATPases stimulate
catalytic phosphorylation and expose a targeting signal leading
to initiation of trafficking to their respective destinations within
the cell. Furthermore, the MBSs closest to the first transmembrane
domain are required for this process. Taken together, these stu-
dies suggest that the mechanism for copper translocation and
trafficking are coupled and are highly conserved between the cop-
per CPx-type ATPases. Further studies are now aimed at eluci-
dating the precise molecular signals in the vicinity of MBSs 5 and
6, which govern the targeting of these two CPx-type ATPases.
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